A scientific review reports that engineered nanocarriers can shield therapeutic probiotics through gastrointestinal digestion, preserving more than 90% viability in cited experiments. The work frames a delivery problem central to probiotic efficacy in clinical studies, particularly where transit conditions and bile/enzymes can inactivate bacterial payloads. Beyond survivability, the review highlights how encapsulation platforms may enable more targeted or sustained exposure profiles in inflammatory and oncology settings. It also discusses translational constraints such as manufacturing consistency, release kinetics, and regulatory considerations for live biotherapeutic approaches. The take-away for developers is that formulation—not just strain selection—may drive whether probiotics achieve clinically meaningful effects.
Get the Daily Brief